Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K+ channels

Zhang,Shuai; Liu,Bo; Fan,Zaiwen; Wang,Dong; Liu,Ying; Li,Jian; Wang,Ning; Liu,Yi; Zhang,Bo

doi:10.3892/mmr.2016.4977

Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K+ channels

Authors:
- Shuai Zhang
- Bo Liu
- Zaiwen Fan
- Dong Wang
- Ying Liu
- Jian Li
- Ning Wang
- Yi Liu
- Bo Zhang
View Affiliations

Affiliations: Department of Respiratory Medicine, General Hospital of PLA Air Force, Beijing 100142, P.R. China
Published online on: March 4, 2016 https://doi.org/10.3892/mmr.2016.4977
Pages: 3415-3422
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypoxic pulmonary hypertension (PH) is a common disease characterized by a disturbance to the balance of apoptosis and cell proliferation in pulmonary artery smooth muscle cells (PASMCs). The anti-apoptotic protein, survivin, has been observed to be upregulated in pulmonary arteries (PAs) of chronic hypoxia-induced PH rats. The present study aimed to investigate the therapeutic potential of sepantronium bromide (YM155), a selective survivin inhibitor, on hypoxic human PASMCs and examine the potential underlying mechanisms. Cultured human PASMCs (HPASMCs) were randomly divided into the following groups: i) Normoxia (N); ii) normoxia + 100 nmol/l YM155 (NY100); iii) hypoxia (H); iv) hypoxia + 1 nmol/l YM155 (HY1); v) hypoxia + 10 nmol/l YM155 (HY10); and hypoxia + 100 nmol/l YM155 (HY100) groups. The cells were exposed to the different conditions for 24 h, according to the group. Cell viability was then determined using a Cell Counting Kit‑8 assay, and apoptosis was detected using a terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling assay. The expression levels of survivin were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), immunocytochemistry and Western blot analyses. The expression levels of the voltage-dependent K+ (Kv) channels, Kv1.5 and Kv2.1, were measured using RT-qPCR and Western blotting. Cell proliferation in the hypoxic PASMCs was significantly increased by hypoxia, however, apoptosis of the HPASMCs was suppressed, the expression of survivin were upregulated and the expression levels of Kv1.5 and Kv2.1 were downregulated. YM155 treatment ameliorated the hypoxia‑induced increase in cell proliferation and expression of survivin in a concentration‑dependent manner, increased apoptosis, and increased the expression levels of Kv1.5 and Kv2.1 (P<0.05). By contrast, YM155 treatment in normoxic HPASMCs had no significant effects on proliferation, apoptosis, or the expression levels of survivin and Kv channels in the PASMCs. The present study is the first, to the best of our knowledge, to demonstrate that YM155, a selective survivin inhibitor, has a beneficial therapeutic effect on hypoxic HPASMCs, and that YM155 induces a pro‑apoptotic effect by downregulating the apoptosis inhibitor, survivin, possibly through a Kv channel-mediated mechanism.

View Figures

View References

1	Guignabert C and Dorfmuller P: Pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med. 34:551–559. 2013. View Article : Google Scholar : PubMed/NCBI
2	McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K and Michelakis ED: Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 95:830–840. 2004. View Article : Google Scholar : PubMed/NCBI
3	Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL and Shimoda LA: Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca²⁺ in pulmonary arterial smooth muscle cells. Circ Res. 98:1528–1537. 2006. View Article : Google Scholar : PubMed/NCBI
4	Hu HL, Zhang ZX, Chen CS, Cai C, Zhao JP and Wang X: Effects of mitochondrial potassium channel and membrane potential on hypoxic human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 42:661–666. 2010. View Article : Google Scholar
5	Chen C, Chen C, Wang Z, Wang L, Yang L, Ding M, Ding C, Sun Y, Lin Q, Huang X, et al: Puerarin induces mitochondria-dependent apoptosis in hypoxic human pulmonary arterial smooth muscle cells. PLoS One. 7:e341812012. View Article : Google Scholar : PubMed/NCBI
6	Yung GL: Evaluation of patients with pulmonary hypertension for lung transplantation. Textbook of Pulmonary Vascular Disease. Yuan JXJ, Garcia JGN, Hales CA, Rich S, Archer SL and West JB: Springer; New York, NY: pp. 1593–1598. 2011, View Article : Google Scholar
7	Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG and Weir EK: Mitochondrial metabolism, redox signaling and fusion: A mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. AM J Physiol Heart Circ Physiol. 294:H570–H578. 2008. View Article : Google Scholar
8	Park WS, Firth AL, Han J and Ko EA: Patho-, physiological roles of voltage-dependent K⁺ channels in pulmonary arterial smooth muscle cells. J Smooth Muscle Res. 46:89–105. 2010. View Article : Google Scholar
9	Altieri DC: Validating survivin as a cancer therapeutic target. Nature Reviews Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
10	Zyada MM: Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region. Med Oncol. 28:1565–1569. 2011. View Article : Google Scholar
11	Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar : PubMed/NCBI
12	Salvesen GS and Duckett CS: IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol. 3:401–410. 2002. View Article : Google Scholar : PubMed/NCBI
13	Hingorani P, Dickman P, Garcia-Filion P, White-Collins A, Kolb EA and Azorsa DO: BIRC5 expression is a poor prognostic marker in ewing sarcoma. Pediatr Blood Cancer. 60:35–40. 2013. View Article : Google Scholar
14	McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L and Michelakis ED: Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 115:1479–1491. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ryan BM, O'Donovan N and Duffy MJ: Survivin: A new target for anti-cancer therapy. Cancer Treat Rev. 35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H and Sasamata M: YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol. 39:569–575. 2011.PubMed/NCBI
17	Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L, Cao L, Xiao PF, Pang L, Wu D, et al: Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer. 12:6192012. View Article : Google Scholar : PubMed/NCBI
18	Liu B, Fan Z, Li J, Liu Y, Wang N, Wang D, Liu Y and Zhang B: Expression of survivin in pulmonary artery of rats exposed to normoxia and hypoxia. International Journal of Respiration. 33:994–998. 2013.
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Paulin R, Courboulin A, Meloche J, et al: Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 123:1205–1215. 2011. View Article : Google Scholar : PubMed/NCBI
21	Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM and Voelkel NF: Gene expression patterns in the lungs of patients with primary pulmonary hypertension: A gene microarray analysis. Circ Res. 88:555–562. 2001. View Article : Google Scholar : PubMed/NCBI
22	Altieri DC: Targeting survivin in cancer. Cancer Lett. 332:225–228. 2013. View Article : Google Scholar :
23	Stauber RH, Mann W and Knauer SK: Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic and therapeutic potential. Cancer Res. 67:5999–6002. 2007. View Article : Google Scholar : PubMed/NCBI
24	Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A and Bonnet S: Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 301:H1798–H1809. 2011. View Article : Google Scholar : PubMed/NCBI
25	Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G, Hamon M, Adnot S and Eddahibi S: Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 94:1263–1270. 2004. View Article : Google Scholar : PubMed/NCBI
26	Ekhterae D, Platoshyn O, Krick S, Yu Y, McDaniel SS and Yuan JX: Bcl-2 decreases voltage-gated K⁺ channel activity and enhances survival in vascular smooth muscle cells. Am J Physiol Cell Physiol. 281:C157–C165. 2001.PubMed/NCBI
27	Reid L: Vascular remodeling. The Pulmonary Circulation: Normal and Abnormal Mechansimc, Management and the National Registry. Fishman A: University of Pennsylvania Press; Philadelphia, PA: pp. p2641990
28	Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
29	Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ and Yuan JX: Cellular and molecular mechanisms of pulmonary vascular remodeling: Role in the development of pulmonary hypertension. Microvasc Res. 68:75–103. 2004. View Article : Google Scholar : PubMed/NCBI
30	Fernandez RA, Sundivakkam P, Smith KA, Zeifman AS, Drennan AR and Yuan JX: Pathogenic role of store-operated and receptor-operated ca(²⁺) channels in pulmonary arterial hypertension. J Signal Transduct. 2012:9514972012. View Article : Google Scholar
31	Gurbanov E and Shiliang X: The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur J Cardiothorac Surg. 30:499–507. 2006. View Article : Google Scholar : PubMed/NCBI
32	Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R and Archer SL: Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation. 105:244–250. 2002. View Article : Google Scholar : PubMed/NCBI
33	Moudgil R, Michelakis ED and Archer SL: The role of K⁺ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation and apoptosis: Implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation. 13:615–632. 2006. View Article : Google Scholar : PubMed/NCBI
34	Sweeney M and Yuan JX: Hypoxic pulmonary vasoconstriction: Role of voltage-gated potassium channels. Respir Res. 1:40–48. 2000. View Article : Google Scholar
35	Pozeg ZI, Michelakis ED, McMurtry MS, Thébaud B, Wu XC, Dyck JR, Hashimoto K, Wang S, Moudgil R, Harry G, et al: In vivo gene transfer of the O₂-sensitive potassium channel Kv1. 5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation. 107:2037–2044. 2003. View Article : Google Scholar : PubMed/NCBI